Table 1 

Clinicopathological features of patients with AITLdeveloped secondary EBVassociated B cell lymphoma described in present and previous reports 

caseNo. 
Authors (yr.) 
Age/sex 
Tumor site 
Interval (mo) 
Histotype of BCL* 
Treatment 
Clinical Outcome 




AITL 
BCL 
AITL 
BCL 



1 
Abruzzo LV (1993) [4] 
46/M 
LN 
SK 
26 
Largecell immunoblastic type 
Cyclophosphamide 
N/D 
Died of multiorgan failure 
2 
Park S (2002) [5] 
55/F 
LN 
LN 
48 
BCL 
CHOP 
CHOPR 
CR and alive 12 mo later 
3 
Xu Y (2002) [6] 
48/F 
LN 
LN 
0 
DLBCL 
CHOP and ESHAP 
CR and relapsed a few months later 

4 
Zettl A (2002) [7] 
68/M 
LN 
ST 
34 
DLBCL 
Observation 
Glucocorticoids 
Died 4 mo later of tuberculosis 
5 
47/M 
LN 
LN 
29 
DLBCL 
CC; BMT 
CC; involved field radiation 
Died 3 mo later of Aspergillus pneumonia 

6 
61/M 
LN 
LN 
96 
Plasmacytoma 
N/Av 
N/Av 
Alive with disease 24 mo later 

7 
Hawley RC (2006) [8] 
69/F 
LN 
SK 
56 
DLBCL 
CHOP 
RhyperCVAD 
Died 54 mo later 
8 
Attygalle AD (2007) [9] 
28/M 
LN 
BM 
24 
DLBCL 
CHOP 
Gemcitabine 
No response and died 3 mo later 
9 
60/F 
LN 
LN 
8 
DLBCL 
CHOP 
CHOPEt 
No response and died 3 mo later 

10 
59/M 
LN 
LN 
8 
DLBCL 
N/Av 
CC 
PR and alive with disease 68 mo later 

11 
72/M 
LN 
LN 
84 
DLBCL 
N/Av 
N/Av 
N/A 

12 
78/F 
LN 
LN 
0 
DLBCL 
Thalidomide 
PR 

13 
Willenbrock K (2007) [10] 
76/F 
LN 
LN 
8 
DLBCL 
N/Av 
N/Av 
N/Av 
14 
46/F 
LN 
BM 
5 
DLBCL 
N/Av 
N/Av 
N/Av 

15 
84/M 
LN 
LN 
0 
DLBCL 
N/Av 
N/Av 
N/Av 

16 
72/M 
LN 
LN 
0 
DLBCL 
N/Av 
N/Av 
N/Av 

17 
65/M 
LN 
LN 
0 
CD30positive BCL 
N/Av 
N/Av 
N/Av 

18 
60/F 
LN 
LN 
0 
DLBCL 
N/Av 
N/Av 
N/Av 

19 
Weisel KC (2008) [11] 
59/M 
LN 
DB and lung 
11 
DLBCL 
Fudarabine+ CHOP 
N/D 
Died 2 weeks later 
20 
Takahashi T (2010) [12] 
66/F 
LN 
Ileum 
24 
DLBCL 
THPCOP CHASE 
N/D 
Died 1 mo later of respiratory failure 
21 
Skugor ND (2010) [13] 
36/F 
LN 
LN 
11 
DLBCL 
FED 
CHOPR and stem cell transplantation 
CR 
22 
Huang J (2011) [14] 
64/M 
LN 
LN 
47 
DLBCL 
IHOP 
CHOPR 
Alive with disease 13 mo later 
23 
Present case 
65/M 
LN 
SK 
19 
DLBCL 
CHOP 
CHOPR 
PR 


*, all Bcell lymphoma with EBV positive; AITL, angioimmunoblastic Tcell lymphoma; BCL, Bcell lymphoma; DLBCL, diffuse large Bcell lymphoma; LN, lymph node; SK, skin; ST, soft tissue; BM, bone marrow; DB, Duodenal bulbus; Interval 0, AITL with simultaneous Bcell lymphoma or primary Bcell lymphoma in the background of AITL; BMT, bone marrow transplantation; N/Av, not available; N/D, not done; PR, partial response; CR, complete remission; CHOP, cyclophosphamide, vincristine, adriamycin, and prednisone; ESHAP, etoposide, methyl prednisolone, cytarabine (araC) and cisplatin; hyperCVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; IHOP, ifosfamide, doxorubicin, vincristine, and prednisone; THPCOP, cyclophosphamide, pirarubicin, vincristine, prednisolone; CHASE, cyclophosphamide, cytarabine, etoposide, dexamethasone; FED, fludarabine, cyclophosphamide, dexamethasone; Et, etoposide; R, rituximab; CC, combination chemotherapy, details not available; 

Yang et al. Diagnostic Pathology 2012 7:7 doi:10.1186/1746159677 